New hope for rare lung disease: triple therapy trial launches
NCT ID NCT07443436
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of three drugs (prednisone, azithromycin, and hydroxychloroquine) can slow lung function decline in adults with interstitial lung disease caused by certain gene variants. About 30 participants will receive either the triple therapy or standard care for 12 months. The main goal is to see if the combo helps preserve breathing capacity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI catch lung scarring that doctors might miss?
- Can arm workouts boost oxygen use in lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- Virtual Nurse-Social worker team aims to ease symptoms for veterans with heart failure and COPD
- AI outruns radiologists in detecting early lung scarring
- Smart home tech could help lung patients breathe easier at home